Hydroxychloroquine Market Size, Share, Growth 2021-2026

According to the latest report by IMARC Group, titled “Hydroxychloroquine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026″, The global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026.

Hydroxychloroquine (HCQ) is a derivative of chloroquine that is primarily used to treat or prevent malaria. It is also used in the treatment of numerous autoimmune diseases, such as systemic and discoid lupus erythematosus and rheumatoid arthritis. It exhibits endothelial stabilizing and anti-thrombotic effects as it containsantigens and cytokines.

Request Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample

Hydroxychloroquine Market Trends

The global market is majorly driven by the outbreak of the COVID-19 pandemic across the globe. Hydroxychloroquine has gained widespread prominence due to its effectiveness in the treatment of COVID-19 patients, thereby providing an impetus to the market growth. Furthermore, the increasing prevalence of malaria and other chronic disorders is providing a thrust to the market growth. Along with this, the rapidly rising cases of autoimmune diseases, and the escalating demand for generic drugs are further providing an impetus to the market growth. Other factors, including increasing investments by the governments of several countries to improve the overall healthcare infrastructure and extensive research and development (RD) activities, are also projected to drive market growth.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Dosage Type:

  • 200 Mg
  • 300 Mg
  • 400 Mg
  • Others

Breakup by Distribution:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Application:

  • Rheumatoid Arthritis
  • Lupus Erythematosus
  • Malaria
  • Coronavirus (COVID-19)
  • Others

Breakup by Grade:

  • USP Standards Grade
  • EP Standards Grade
  • Pharmaceutical Standards Grade
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape Key Player:

  • Amneal Pharmaceuticals Inc.
  • Cardinal Health Inc.
  • Cipla Ltd.
  • Ipca Laboratories Ltd.
  • Laurus Labs
  • Lupin Limited
  • Mylan N.V.
  • Novartis AG
  • Prasco Laboratories
  • Dr. Reddy’s Laboratories Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharma
  • Zydus Cadila

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=2266&flag=C

Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group